Ten

BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jul 11, 2007 - BioSantePharmaceuticals, Inc. (Amex: BPA) today announced new positiveresults demonstrating that its calcium phosphate (CaP)nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as aneffective vaccine adjuvant for the development of a dose sparingvaccine against H5N1 avian flu, widely known as bird flu. The new results are based on...

New Information on the Potential of Plasmin Shared at ISTH Congress

RESEARCH TRIANGLE PARK, N.C. & GENEVA--(BUSINESS WIRE)--Jul 11,2007 - New information representing the continuing research anddevelopment program for Plasmin (Human), TAL-05-00018, waspresented by Talecris Biotherapeutics, Inc.(http://www.talecris.com) this week at the XXIst InternationalSociety for Thrombosis and Haemostasis (ISTH) Congress in Geneva,Switzerland. The information includ...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1cReductions Observed in Phase 3 CARISA and MERLIN TIMI-36 ClinicalTrials -- PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that researchers have completedpreliminary preclinical studies showing that ranolazine increasedglucose stimulated insulin secretion in pancreatic beta cells...

Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

SAN DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Metabasis Therapeutics(NASDAQ:MBRX), a biopharmaceutical company focused on thediscovery, development and commercialization of novel drugs for thetreatment of metabolic and liver diseases by targeting the liverand liver pathways, announced today that John Beck, senior vicepresident of finance and chief financial officer of Metabasis willpresent at t...

YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy

MISSISSAUGA, ON, July 09, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced that a study presented by investigators from KinkiUniversity School of Medicine and Kyoto University at the 11thmeeting of The Japanese Association for Molecular Target Therapy ofCancer...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

EXCLAIM is the First International Study to Show That ExtendedThromboprophylaxis Reduces VTE Risk in Acutely-ill Medical PatientsWith a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced today the results of the EXCLAIM (EXtended CLinicalprophylaxis in Acutely Ill Medical patients) study, which showedthe benefit of extended prophylaxi...

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI, FL -- (MARKET WIRE) -- July 06, 2007 -- DOR BioPharma,Inc. (OTCBB: <a target="_blank" href='http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB )("DOR" or the "Company") announced today that the European PatentOffice has granted a paten...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN)("CeNeS" or "the Company") the Cambridge-based biopharmaceuticalcompany today announced that a paper published this week in CNSDrugs(1) further supports the hypothesis that acatechol-O-methyltransferase (COMT) inhibitor that acts in thebrain would be a useful agent to address profound cognitivedeficits in schizophrenia and bi...

Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and WyethPharmaceuticals, a division of Wyeth (NYSE: WYE), today announcedpositive results from a three-month open-label extension study ofsubcutaneous methylnaltrexone for the treatment of opioid-inducedconstipation (OIC) in patients with advanced illness. The resultsare sched...

Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Next Generation Renin Inhibitor to Continue Phase II Profilingin Diabetic Patients BASEL/Switzerland and BRIDGEWATER NJ/USA, 28 June 2007-Speedel(SWX: SPPN) today announced that it has reached another significantmilestone in the development of its family of renin inhibitors withthe successful completion of a Phase IIa proof-of-concept clinicaltrial with SPP635 for the treat...

CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corporation(NASDAQ:CYTR), a biopharmaceutical company engaged in thedevelopment and commercialization of human therapeutics, todayannounced promising data from the six-month, open-label extensionof its completed Phase IIa clinical trial with arimoclomol in ALSvolunteers. While the clinical trial was not placebo-controlled,arimoclomol at a 1...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Expert Opinion Highlights Avigen's AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal

Focus On AV411's Unique Mechanism of Action and Broad Potential forthe Treatment of Neurological Conditions ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc.(Nasdaq:AVGN), a biopharmaceutical company innovating therapeuticsfor the treatment of neurological conditions, announced today thatExpert Opinion on Investigational Drugs has published an articlefeaturing...

New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes

* Significant blood sugar reductions seen across range ofpatient populations, including varied ethnic groups, the elderly,and those at high risk of developing diabetes * Galvus lowers blood sugar when added to a sulfonylurea,reinforcing efficacy in combination with commonly used diabetesmedicines * Data confirm good tolerability in humans with studies showingincidence of sid...

Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

- ARI-2243 is an highly potent DPP-4 inhibitor, possessing Ki of 27pM BOSTON, June 25, 2007 /PRNewswire/ -- Arisaph Pharmaceuticals,Inc., a privately held drug discovery biopharmaceutical company,announced today the results of its potent, smart DPP-4 inhibitor,ARI-2243, presented at the 67th session of the American DiabetesAssociation meeting in Chicago, Illinois. The results showed that...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 21, 2007 - OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, todayannounced positive top-line data in an open-label Phase I/IIextension clinical trial of the investigational T-cell vaccine,Tovaxin(TM), for multiple sclerosis (MS). In this one-year,8-subject extension clinical trial...

New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

RIDGEFIELD, Conn., June 18, 2007 /PRNewswire/ -- Today, resultsfrom AMADEO*, one of a series of studies comparing two angiotensinreceptor blockers (ARBs) in hypertensive patients with diabeticnephropathy, were presented at the 17th annual European Meeting onHypertension in Milan, Italy. The randomized, double-blind, forced titration, parallel group,multicenter study included 860 hy...

New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes

MILAN, Italy, June 15 /CNW/ - Today AMADEO, one of thefirst studies to compare the protective potential of twoangiotensin receptor blockers in hypertensive patients withdiabetic nephropathy, was presented at the European Societyof Hypertension, Milan. The results from this study show that telmisartan reduces proteinuria to a significantly greater extentthan losartan.(1)...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25/ - 13 mm Hg (systolic / diastolic, p - Blood pressure reduction dependent on vaccine dose and inducedantiangiotensin II antibody levels - Detailed results presented today at the Seventeenth EuropeanMeeting on Hypertension in Milan, Italy SCHLIEREN (Zurich), Switzerland and MILAN, Ita...

Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

* New data from 741-patient trial show those treated withPrexige experienced significantly smaller impact on blood pressurecompared to ibuprofen[1] * Many patients with osteoarthritis also have high bloodpressure; even small changes in blood pressure can impactcardiovascular risk[2],[3] * Prexige approved in more than 50 countries and currently underreview in US for use in o...

Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

New data From 741-patient Trial Show Those Treated with LumiracoxibExperienced Significantly Smaller Impact on Blood Pressure Comparedto Ibuprofen EAST HANOVER, N.J., June 15, 2007 /PRNewswire/ -- Patients withosteoarthritis who also have controlled hypertension experienced aslight decrease in average daily blood pressure when treated withthe investigational selective COX-2 inhibitor lumi...

Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo

Demonstrates Positive Effect on Objective and Subjective SleepMeasures MINNEAPOLIS, June 13, 2007 /PRNewswire-FirstCall/ -- Accordingto study results presented today at SLEEP 2007, the 21st annualmeeting of the Associated Professional Sleep Societies (APSS),VEC-162, a balanced melatonin (MT1/MT2) receptor agonist beingdeveloped by Vanda Pharmaceuticals Inc. , demonstrated improvementsin...

Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's Disease

NEW YORK--(BUSINESS WIRE)--Jun 14, 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicatedto the commercialization of products for a variety of malignant,degenerative and auto-immune indications, announced today thatPluristem's PLacenta eXpanded (PLX) cells have been demonstrated invitro to have properties that the Company believes gives thesecells th...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective atKilling CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab(Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, announces that a researchpaper showing the potential of its TH-1 technology for targetedcancer therapy has been published by the leading medical journal,...

Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - CriticalTherapeutics, Inc. (Nasdaq: CRTX) today announced the publicationof data from a pivotal Phase III clinical trial of ZYFLO CR(TM)(zileuton) extended-release tablets in the June 2007 issue of theJournal of Asthma. ZYFLO CR was approved by the U.S. Food and DrugAdministration (FDA) on May 30, 2007. Critical Therapeutics,together with it...

To Stent or Not: Is That the Question?

Reporting of COURAGE study results confused the public about theneed and benefits of angioplasty PORTLAND, Ore., June 07, 2007 /PRNewswire/ -- The onslaught ofanti-stent news reports over the past few months has shaped thepublic's view that angioplasty doesn't work and its use shoulddecrease. Confused by the media coverage, patients have extensivelyquestioned their cardiologists about the...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today the companydelivered multiple presentations on preclinical study results andnew device innovations relating to its electroporation-mediated DNAdelivery te...

Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection

Study Shows Safety and Pharmacokinetics Similar to IV Doses inPhase 3 CLL Trial BERKELEY HEIGHTS, N.J., June 06, 2007 /PRNewswire-FirstCall/ --Genta Incorporated announced the publication of preliminaryclinical results that show the Company's lead anti-cancer drug,Genasense(R) (oblimersen sodium) injection, can be safelyadministered by intermittent subcutaneous (SC) injection, as wellas...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

NEW YORK--(BUSINESS WIRE)--Jun 5, 2007 - ERBITUX (cetuximab), thefirst approved IgG1 monoclonal antibody targeting the epidermalgrowth factor receptor (EGFR) developed and commercialized byImClone Systems Incorporated, was the focus of nine oral and 46poster presentations at the recently concluded 43rd Annual Meetingof the American Society of Clinical Oncology (ASCO). This year's ASCO ERB...

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - ElixirPharmaceuticals, Inc., announced today new preclinical dataconfirming ghrelin antagonism as a potential method for regulatingmetabolism, decreasing body weight and managing blood glucose. Thedata were presented in poster sessions during ENDO 07, TheEndocrine Society's 89th Annual Meeting, being held in Toronto,Canada. Elixir is focused...

Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer

CHICAGO - June 3, 2007 - Schering-Plough Corp. announced resultsfrom a Phase III study that showed maintenance chemotherapy withCaelyx (pegylated liposomal doxorubicin hydrochloride)significantly prolonged time to progression (TTP) in patients withmetastatic breast cancer with infrequent and manageable clinicaltoxicity after first-line chemotherapy. These data were presentedtoday at the...

Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas

SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of data from apreclinical study of novel monoclonal antibodies against thecell-surface protein NTB-A. The data demonstrate that NTB-A is apotential new target for immunotherapy of B-cell malignanciesincluding leukemia and lymphomas. The study, entitled "The lymphoidcell surface recepto...

New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings

Registry Analysis Published in Journal Heart Finds Taxus Stent,Implantation of Multiple Stents and Small Vessel Size To BeIndependent Predictors of Need for Another Procedure MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX NewsNetwork/ -- An analysis of data from the Western Denmark HeartRegistry found that patients who received the CYPHER(R)Sirolimus-eluting Coronary...

Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment

COPENHAGEN, June 3, 2007 - Genmab A/S (CSE: GEN) announcedtoday pre-clinical data illustrating its fully humanHuMax-EGFr™ (zalutumumab) antibody may have broad potentialto treat cancers that over-express several types of EGFr (epidermalgrowth factor receptor). Recently, mutations which appear to alter the signaling abilityof EGFr have been identified in tumors from lung canc...

Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- BostonScientific Corporation today welcomed the publication of an articlein the Journal of of Cardiology (JACC) reviewing the TAXUS ATLASclinical trial, which evaluates the Company's second-generationTAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. Thearticle in the April 24 edition of JACC concluded that the shorterprocedure...

Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients

- First Agent Ever to Demonstrate Significant Survival Benefit inLiver Cancer - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- BayerHealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc.today announced that Nexavar(R) (sorafenib) tablets significantlyextended overall survival in patients with hepatocellular carcinoma(HCC), or primary liver cancer versus those taking placebo by 4...

MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone

Seven year follow up of pivotal trial confirms that more patientsare alive today due to MabThera BASEL, Switzerland, June 4, 2007-A follow-up analysis trackingthe outcome of patients with aggressive non-Hodgkin's lymphoma(NHL) who were treated with the innovative cancer therapy MabThera(rituximab) over seven years ago has revealed exciting results(1). This analysis of the original...

New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients

Aggrenox® (Asasantin® Retard) considered by many asfirst-line in secondary stroke prevention INGELHEIM, Germany, 31 May 2007 - New data presented today at the16th European Stroke Conference in Glasgow confirm that therapywith dipyridamole plus ASA (extended-release dipyridamole plus ASAis marketed as Aggrenox® or Asasantin® Retard) is superiorto ASA* alone in...